Schering-Plough research head Thomas Koestler says his company is "pretty excited" by the trial results so far for its hepatitis C protease inhibitor drug boceprevir and plans to share data with regulators soon to discuss next steps.

FORBES: Magazine Article

Many eye-vitamin formulations currently on the market are based on research conducted by the National Institutes of Health in a project called Age-Related Eye Disease Study, or AREDS. The first phase of the clinical trial, completed in 2001, found that a specific combination of vitamins C and E, along with beta-carotene and zinc, reduced the risk of age-related macular degeneration by as much as 25%.

WSJ: The Crucial Years for Protecting Your Eye Health